SPC
CUE icon

Sigma Planning Corp’s Cue Biopharma CUE Stock Holding History

Sigma Planning Corp’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.91K Sell
1,292
-76
-6% -$709 ﹤0.01% 1306
2025
Q4 		$12.5K Sell
1,368
-409
-23% -$7.51K ﹤0.01% 1291
2025
Q3 		$38.3K Sell
1,777
-73
-4% -$1.71K ﹤0.01% 1282
2025
Q2 		$37.9K Sell
1,850
-9,025
-83% -$193K ﹤0.01% 1235
2025
Q1 		$297K Sell
10,875
-4,031
-27% -$150K 0.01% 951
2024
Q4 		$487K Buy
14,906
+1,528
+11% +$57.4K 0.02% 752
2024
Q3 		$304K Buy
13,378
+4,510
+51% +$97.7K 0.01% 945
2024
Q2 		$330K Buy
8,868
+334
+4% +$16.5K 0.01% 885
2024
Q1 		$484K Buy
8,534
+4,905
+135% +$346K 0.02% 776
2023
Q4 		$287K Sell
3,629
-4,528
-56% -$324K 0.02% 634
2023
Q3 		$563K Buy
8,157
+647
+9% +$63.2K 0.02% 660
2023
Q2 		$822K Buy
7,510
+147
+2% +$17.3K 0.03% 538
2023
Q1 		$789K Buy
7,363
+939
+15% +$89.6K 0.03% 610
2022
Q4 		$549K Buy
6,424
+143
+2% +$13.1K 0.02% 729
2022
Q3 		$420K Buy
6,281
+711
+13% +$61.2K 0.02% 802
2022
Q2 		$416K Buy
5,570
+1,246
+29% +$146K 0.01% 828
2022
Q1 		$633K Buy
4,324
+1,461
+51% +$310K 0.02% 741
2021
Q4 		$971K Buy
2,863
+55
+2% +$21.3K 0.03% 557
2021
Q3 		$1.23M Buy
2,808
+85
+3% +$29.6K 0.04% 475
2021
Q2 		$952K Buy
2,723
+287
+12% +$111K 0.03% 571
2021
Q1 		$892K Buy
2,436
+50
+2% +$20.6K 0.03% 549
2020
Q4 		$895K Buy
2,386
+392
+20% +$157K 0.03% 472
2020
Q3 		$900K Buy
1,994
+225
+13% +$130K 0.04% 428
2020
Q2 		$1.3M Sell
1,769
-439
-20% -$318K 0.06% 321
2020
Q1 		$940K Buy
2,208
+29
+1% +$14.1K 0.06% 335
2019
Q4 		$1.04M Buy
2,179
+172
+9% +$54K 0.04% 394
2019
Q3 		$508K Buy
2,007
+413
+26% +$99.2K 0.02% 566
2019
Q2 		$430K Buy
1,594
+191
+14% +$47.5K 0.02% 595
2019
Q1 		$325K Buy
+1,403
New +$267K 0.02% 648

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Sigma Planning Corp's CUE Position: Q1 2026 in Review

Sigma Planning Corp reduced its Cue Biopharma (CUE) stake by 5.6% in Q1 2026, selling an estimated $709 and leaving 1,292 shares worth $8.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Sigma Planning Corp first reported a position in CUE in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.3M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Sigma Planning Corp held 1,292 shares of Cue Biopharma worth $8.91K as of Q1 2026.
  • Sigma Planning Corp sold 76 Cue Biopharma shares in Q1 2026, an estimated $709.
  • Cue Biopharma made up ﹤0.01% of Sigma Planning Corp's portfolio in Q1 2026, its #1306 holding.
  • Sigma Planning Corp first reported a position in Cue Biopharma in Q1 2019 and has held it in 29 quarters since.
  • Sigma Planning Corp's Cue Biopharma position peaked at $1.3M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.